Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
暂无分享,去创建一个
R. Price | D. Isenberg | B. Hazleman | T. Kishimoto | G. Panayi | E. Choy | H. Bird | K. Yoshizaki | N. Nishimoto | B. Williams | B. Williams | Y. Ioannou | T. Garrood | S. Farrow | H. Bird | N. Cheung